Table 4 |
|||||||||
|
Spearman rank correlations of changes in laboratory results from baseline to 24 months in postmenopausal women with rheumatoid arthritis who were given HRT |
|||||||||
|
Test |
TNF-α |
IL-1Ra |
IL-6 |
sIL-6R |
IGF-1 |
ESR |
Estradiol |
BMD total hip |
BMD lumbar spine |
|
|
|||||||||
|
Serum TNF-α (pg/ml) |
– |
0.303** |
0.108 |
0.245* |
-0.258* |
0.310** |
-0.263* |
0.169 |
-0.132 |
|
Serum IL-1Ra (pg/ml) |
0.303** |
– |
0.313** |
0.050 |
-0.222 |
0.122 |
0.012 |
0.075 |
-0.126 |
|
Serum IL-6 (pg/ml) |
0.108 |
0.313** |
– |
0.041 |
-0.061 |
0.421*** |
0.188 |
0.081 |
0.078 |
|
Serum sIL-6R (pg/ml) |
0.245* |
0.050 |
0.041 |
– |
-0.137 |
0.119 |
-0.263* |
-0.132 |
-0.278* |
|
Serum IGF-1 (ng/ml) |
-0.258* |
-0.222 |
-0.061 |
-0.137 |
– |
-0.250* |
0.179 |
0.200 |
0.195 |
|
ESR (mm) |
0.310** |
0.122 |
0.421*** |
0.119 |
-0.250* |
– |
-0.079 |
-0.092 |
-0.145 |
|
Serum estradiol (pmol/l) |
-0.263* |
0.012 |
0.188 |
-0.263* |
0.179 |
-0.079 |
– |
0.491*** |
0.483*** |
|
|
|||||||||
|
*P < 0.05, **P < 0.01, ***P < 0.001. BMD = bone mineral density; ESR = erythrocyte sedimentation rate; IGF-1 = insulin-like growth factor 1; IL-1Ra = IL-1-receptor antagonist; sIL-6R = soluble IL-6 receptor; TNF-α = tumor necrosis factor α. |
|||||||||
|
d'Elia et al. Arthritis Res Ther 2003 5:R202 doi:10.1186/ar761 |
|||||||||